May 10, 2023
Neuronetics to Present at the JMP Securities Life Sciences Conference
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical…
Pharmaceuticals, Biotechnology and Life Sciences
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical…
– Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate…
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…
First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy…
Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of…
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced…
ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…
EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the…
Montrouge, France, May 4, 2023 DBV Technologies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and…
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company…